It has been noted HDAC inhibitors as monotherapy were initially incorporated into the clinical exhibits limited effectiveness, acquisition of drug resistance as well as adverse effect in the treatment of cancer [101, 102]. The gene discussed is HDAC9; the disease is cancer.